Personalis Stock Is Up 250% in the Past Year. It Needs to Turn a Profit Next.

Personalis stock has surged 250% over the past year, sparking interest among investors. The company, a cancer genomics firm, focuses on providing molecular data about each patient's cancer and immune response. Despite the strong price appreciation, Personalis remains unprofitable and speculative. Analyst opinions on the stock are mixed, with mixed sentiments and a significant short interest.

Personalis has a 100% Buy technical opinion from Barchart, based on its impressive current momentum and the presence of a Trend Seeker Buy signal. Over the past 52 weeks, the stock has a 3-year high of $18.89 and has gained 248.16%. Currently trading at $17.02, the 50-day moving average stands at $13.65. Personalis has 12 new highs and gained 44.23% in the last month.

Revenue is projected to grow by 18.4% this year and another 33.63% next year, while earnings are estimated to decrease by 20.05% this year but increase by 13.89% next year. Price targets for Personalis range between $10.00 and $16.25, with Value Morningstar rating the stock as 23% undervalued at $22.18. However, the company's operations have not yet turned a profit, making it highly speculative.